Atlas Venture Opportunity Fund I, L.p. - Net Worth and Insider Trading

Atlas Venture Opportunity Fund I, L.p. Net Worth

The estimated net worth of Atlas Venture Opportunity Fund I, L.p. is at least $68 Million dollars as of 2024-11-10. Atlas Venture Opportunity Fund I, L.p. is the 10% Owner of Dyne Therapeutics Inc and owns about 2,306,079 shares of Dyne Therapeutics Inc (DYN) stock worth over $66 Million. Atlas Venture Opportunity Fund I, L.p. is also the 10% Owner of Xilio Therapeutics Inc and owns about 2,759,344 shares of Xilio Therapeutics Inc (XLO) stock worth over $3 Million. Details can be seen in Atlas Venture Opportunity Fund I, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Atlas Venture Opportunity Fund I, L.p. has not made any transactions after 2024-03-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Atlas Venture Opportunity Fund I, L.p.

To

Atlas Venture Opportunity Fund I, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Atlas Venture Opportunity Fund I, L.p. owns 13 companies in total, including Dyne Therapeutics Inc (DYN) , Kymera Therapeutics Inc (KYMR) , and Magenta Therapeutics Inc (MGTA) among others .

Click here to see the complete history of Atlas Venture Opportunity Fund I, L.p.’s form 4 insider trades.

Insider Ownership Summary of Atlas Venture Opportunity Fund I, L.p.

Ticker Comapny Transaction Date Type of Owner
DYN Dyne Therapeutics Inc 2024-03-01 10 percent owner
KYMR Kymera Therapeutics Inc 2020-08-20 10 percent owner
MGTA Magenta Therapeutics Inc 2020-06-29 other: See remarks
LIMIT LIMIT 2020-06-11 10 percent owner
LIMIT LIMIT 2019-06-19 10 percent owner
LIMIT LIMIT 2019-11-18 other: See Remarks
LIMIT LIMIT 2019-07-19 other: See Remarks
LIMIT LIMIT 2022-12-29 10 percent owner
LIMIT LIMIT 2022-01-06 10 percent owner
LIMIT LIMIT 2021-03-25 10 percent owner
LIMIT LIMIT 2021-10-26 10 percent owner
LIMIT LIMIT 2021-05-26 10 percent owner
LIMIT LIMIT 2022-09-14 10 percent owner

Atlas Venture Opportunity Fund I, L.p. Latest Holdings Summary

Atlas Venture Opportunity Fund I, L.p. currently owns a total of 2 stocks. Among these stocks, Atlas Venture Opportunity Fund I, L.p. owns 2,306,079 shares of Dyne Therapeutics Inc (DYN) as of March 1, 2024, with a value of $66 Million and a weighting of 96.01%. Atlas Venture Opportunity Fund I, L.p. also owns 2,759,344 shares of Xilio Therapeutics Inc (XLO) as of October 26, 2021, with a value of $3 Million and a weighting of 3.99%.

Latest Holdings of Atlas Venture Opportunity Fund I, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DYN Dyne Therapeutics Inc 2024-03-01 2,306,079 28.48 65,677,130
XLO Xilio Therapeutics Inc 2021-10-26 2,759,344 0.99 2,732,026

Holding Weightings of Atlas Venture Opportunity Fund I, L.p.


Atlas Venture Opportunity Fund I, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Atlas Venture Opportunity Fund I, L.p. has made a total of 1 transactions in Dyne Therapeutics Inc (DYN) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Dyne Therapeutics Inc is the sale of 46,534 shares on March 1, 2024, which brought Atlas Venture Opportunity Fund I, L.p. around $1 Million.

According to the SEC Form 4 filings, Atlas Venture Opportunity Fund I, L.p. has made a total of 1 transactions in Xilio Therapeutics Inc (XLO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Xilio Therapeutics Inc is the acquisition of 187,500 shares on October 26, 2021, which cost Atlas Venture Opportunity Fund I, L.p. around $3 Million.

Insider Trading History of Atlas Venture Opportunity Fund I, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Atlas Venture Opportunity Fund I, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Atlas Venture Opportunity Fund I, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atlas Venture Opportunity Fund I, L.p. is -15.32%. GuruFocus also compares Atlas Venture Opportunity Fund I, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Atlas Venture Opportunity Fund I, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Atlas Venture Opportunity Fund I, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Atlas Venture Opportunity Fund I, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 21.03 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 20.6 LIMIT LIMIT LIMIT LIMIT LIMIT

Atlas Venture Opportunity Fund I, L.p. Ownership Network

Ownership Network List of Atlas Venture Opportunity Fund I, L.p.

No Data

Ownership Network Relation of Atlas Venture Opportunity Fund I, L.p.

Insider Network Chart

Atlas Venture Opportunity Fund I, L.p. Owned Company Details

What does Dyne Therapeutics Inc do?

Who are the key executives at Dyne Therapeutics Inc?

Atlas Venture Opportunity Fund I, L.p. is the 10 percent owner of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include director & 10 percent owner Dirk Kersten , See Remarks Richard William Scalzo , and Chief Operating Officer Susanna Gatti High .

Dyne Therapeutics Inc (DYN) Insider Trades Summary

Over the past 18 months, Atlas Venture Opportunity Fund I, L.p. made 1 insider transaction in Dyne Therapeutics Inc (DYN) with a net sale of 46,534. Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 446,445 shares made by Dirk Kersten , a net sale of 327,516 shares made by Richard William Scalzo , and a net sale of 273,683 shares made by Susanna Gatti High .

In summary, during the past 3 months, insiders sold 1,954,064 shares of Dyne Therapeutics Inc (DYN) in total and bought 32,000 shares, with a net sale of 1,922,064 shares. During the past 18 months, 7,985,414 shares of Dyne Therapeutics Inc (DYN) were sold and 1,746,285 shares were bought by its insiders, resulting in a net sale of 6,239,129 shares.

Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Dyne Therapeutics Inc Insider Transactions

No Available Data

Atlas Venture Opportunity Fund I, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Atlas Venture Opportunity Fund I, L.p.. You might contact Atlas Venture Opportunity Fund I, L.p. via mailing address: 400 Technology Square, 10th Floor, Cambridge Ma 02139.